Yu‐Jun Dai

1.1k total citations
25 papers, 488 citations indexed

About

Yu‐Jun Dai is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Yu‐Jun Dai has authored 25 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 12 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Yu‐Jun Dai's work include Acute Myeloid Leukemia Research (11 papers), Epigenetics and DNA Methylation (4 papers) and COVID-19 Clinical Research Studies (3 papers). Yu‐Jun Dai is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Epigenetics and DNA Methylation (4 papers) and COVID-19 Clinical Research Studies (3 papers). Yu‐Jun Dai collaborates with scholars based in China and United States. Yu‐Jun Dai's co-authors include Yang Liang, Sai‐Juan Chen, Yueying Wang, Chen Zhu, Kunhao Bai, Dawei Wang, Siyuan He, Jie Xu, Huan Li and Han-Ying Huang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yu‐Jun Dai

25 papers receiving 480 citations

Peers

Yu‐Jun Dai
Henning D. Popp Germany
Marios Dimitriou Sweden
Giridharan Ramsingh United States
Sabina Pierpaoli Italy
Naïs Prade France
C. Matthias Wilk Switzerland
Sara Pepe Italy
Marcus A. Florez United States
Miori Inoue Japan
Henning D. Popp Germany
Yu‐Jun Dai
Citations per year, relative to Yu‐Jun Dai Yu‐Jun Dai (= 1×) peers Henning D. Popp

Countries citing papers authored by Yu‐Jun Dai

Since Specialization
Citations

This map shows the geographic impact of Yu‐Jun Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu‐Jun Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu‐Jun Dai more than expected).

Fields of papers citing papers by Yu‐Jun Dai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu‐Jun Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu‐Jun Dai. The network helps show where Yu‐Jun Dai may publish in the future.

Co-authorship network of co-authors of Yu‐Jun Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Yu‐Jun Dai. A scholar is included among the top collaborators of Yu‐Jun Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu‐Jun Dai. Yu‐Jun Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gao, Xinjie, et al.. (2025). C3 as a predictive and prognostic biomarker in adult hemophagocytic lymphohistiocytosis: a large cohort study in China. Blood Advances. 9(8). 1836–1846. 1 indexed citations
2.
He, Jiajun, Yilin Liu, Ruonan Shao, et al.. (2025). Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy. npj Precision Oncology. 9(1). 142–142. 1 indexed citations
3.
4.
Shao, Ruonan, et al.. (2023). A novel prognostic prediction model of cuprotosis-related genes signature in hepatocellular carcinoma. Frontiers in Cell and Developmental Biology. 11. 2 indexed citations
5.
Bai, Kunhao, et al.. (2022). Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint. Computational and Structural Biotechnology Journal. 20. 5226–5234. 15 indexed citations
6.
Zhang, Weina, et al.. (2022). Comprehensive analysis of the novel omicron receptor AXL in cancers. Computational and Structural Biotechnology Journal. 20. 3304–3312. 9 indexed citations
7.
8.
Chen, Xiaoqin, Xue‐Ping Li, Siliang Chen, et al.. (2022). Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma. International Immunopharmacology. 108. 108722–108722. 11 indexed citations
9.
Wang, Dawei, Qiang Wang, Xiaohong Pan, et al.. (2021). Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B. SHILAP Revista de lepidopterología. 11(3). e375–e375. 3 indexed citations
10.
Li, Xue‐Ping, et al.. (2021). SARS‐CoV‐2‐related IFITM3 in immune dysfunction and tumor microenvironment: An integrative analysis in pan‐cancers. SHILAP Revista de lepidopterología. 11(2). e345–e345. 2 indexed citations
11.
Yang, Ying, et al.. (2021). DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction between EZH2 and DNMT3A. Biomolecules. 11(6). 781–781. 16 indexed citations
12.
Dai, Yu‐Jun, et al.. (2020). Effects of Alternative Splicing Events on Acute Myeloid Leukemia. DNA and Cell Biology. 39(11). 2040–2051. 8 indexed citations
13.
Dai, Yu‐Jun, et al.. (2020). Epigenetic landscape analysis of lncRNAs in acute myeloid leukemia with DNMT3A mutations. Annals of Translational Medicine. 8(6). 318–318. 10 indexed citations
14.
Bai, Kunhao, Siyuan He, Lingling Shu, et al.. (2020). Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index. Cancer Medicine. 9(12). 4290–4298. 75 indexed citations
15.
Liang, Yang, et al.. (2020). An Immune Risk Score Predicts Survival of Patients with Myelodysplastic Syndrome. Blood. 136(Supplement 1). 33–34. 1 indexed citations
16.
Dai, Yu‐Jun, et al.. (2020). A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection. Annals of Translational Medicine. 8(7). 481–481. 63 indexed citations
17.
Wang, Yun, et al.. (2019). The Role of the HOXA Gene Family in Acute Myeloid Leukemia. Genes. 10(8). 621–621. 50 indexed citations
18.
Zhu, Yongmei, Jinyan Huang, Bing Chen, et al.. (2017). Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance. Journal of Translational Medicine. 15(1). 178–178. 26 indexed citations
19.
Dai, Yu‐Jun, Yueying Wang, Jinyan Huang, et al.. (2017). Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement. Proceedings of the National Academy of Sciences. 114(20). 5237–5242. 55 indexed citations
20.
Xu, Jie, Yueying Wang, Yu‐Jun Dai, et al.. (2014). DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proceedings of the National Academy of Sciences. 111(7). 2620–2625. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Henning D. Popp Breakdown of academic impact, for papers by Marios Dimitriou Breakdown of academic impact, for papers by Giridharan Ramsingh Breakdown of academic impact, for papers by Sabina Pierpaoli Breakdown of academic impact, for papers by Naïs Prade Breakdown of academic impact, for papers by C. Matthias Wilk Breakdown of academic impact, for papers by Sara Pepe Breakdown of academic impact, for papers by Marcus A. Florez Breakdown of academic impact, for papers by Miori Inoue
Rankless by CCL
2026